MedTrace Logo

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

NCT05045027 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-11-14

No results posted yet for this study

Summary

This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

Conditions

  • Glioma
  • Malignant Glioma
  • Recurrent Glioma
  • Recurrent Malignant Glioma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of tissue samples

PROCEDURE

Diagnostic Imaging

Undergo multinuclear metabolic imaging

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Benjamin M Ellingson · UCLA / Jonsson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2026-09-10
Completion
2027-09-10
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05045027 on ClinicalTrials.gov